These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25231690)

  • 41. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
    Bracarda S; Logothetis C; Sternberg CN; Oudard S
    BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.
    Bahl A; Bellmunt J; Oudard S
    BJU Int; 2012 Mar; 109 Suppl 2():14-9. PubMed ID: 22257100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy.
    Rizk R; Danse E; Aydin S; Tombal B; Machiels JP
    Urol Int; 2014; 93(1):49-54. PubMed ID: 24296400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO].
    Ohlmann CH; Gschwend J; Miller K
    Urologe A; 2016 Sep; 55(9):1164-72. PubMed ID: 27431813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The economics of abiraterone acetate for castration-resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):175-9. PubMed ID: 24564607
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Substitution of anti-androgens and tegafur-uracil combination therapy for castration-resistant prostate cancer: results of a multi-center randomized phase II study.
    Takahashi M; Kawabata R; Kawano A; Murakami Y; Sutou Y; Inai T; Akazawa S; Hamao T; Hayashi H; Fukawa T; Takemura M; Yamamoto Y; Yamaguchi K; Izaki H; Fukumori T; Kanayama H
    Int J Oncol; 2013 Sep; 43(3):713-20. PubMed ID: 23817692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]].
    Rexer H
    Urologe A; 2014 Nov; 53(11):1665-7. PubMed ID: 25297491
    [No Abstract]   [Full Text] [Related]  

  • 49. Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?
    Liaw BC; Oh WK
    Nat Rev Clin Oncol; 2015 Jun; 12(6):316-8. PubMed ID: 25917253
    [No Abstract]   [Full Text] [Related]  

  • 50. [Not Available].
    Wolff JM
    Oncol Res Treat; 2017; 40 Suppl 2():11-12. PubMed ID: 28365709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?
    Loriot Y; Massard C; Fizazi K
    Eur Urol; 2014 Oct; 66(4):653-4. PubMed ID: 24735730
    [No Abstract]   [Full Text] [Related]  

  • 52. IMPACT Study: Targeted Prostate Cancer Screening.
    Mikropoulos C; Eeles RA
    Oncologist; 2013; 18(8):e28. PubMed ID: 23986348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance to "castration-resistant".
    Luzzatto L
    Oncologist; 2014 Mar; 19(3):305. PubMed ID: 24536029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?
    Caffo O; Lunardi A; Trentin C; Maines F; Veccia A; Galligioni E
    Curr Drug Targets; 2016; 17(11):1301-8. PubMed ID: 26721408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate cancer: Clinical implications of therapeutic sequence in mCRPC.
    Vaishampayan U
    Nat Rev Urol; 2015 Jan; 12(1):13-4. PubMed ID: 25403243
    [No Abstract]   [Full Text] [Related]  

  • 56. In reply.
    Merseburger AS; Bellmunt J; Jenkins C; Parker C; Fitzpatrick JM
    Oncologist; 2014 Mar; 19(3):305-6. PubMed ID: 24536028
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.
    Heidegger I; Heidenreich A; Pfister D
    Target Oncol; 2017 Feb; 12(1):37-45. PubMed ID: 27796762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.
    Aziz A; Kempkensteffen C; May M; Lebentrau S; Burger M; Chun FK; Brookman-May S
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):649-66. PubMed ID: 25905802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The MAINSAIL trial: an expected failure.
    Boccardo F
    Lancet Oncol; 2015 Apr; 16(4):355-6. PubMed ID: 25743936
    [No Abstract]   [Full Text] [Related]  

  • 60. Ongoing Clinical Trials in Prostate Cancer: The STAMPEDE Trial.
    Oncol Res Treat; 2016; 39(7-8):464-7. PubMed ID: 27487186
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.